Clinical Implications of Recent Data and CAR T-Cell Therapy Approvals in R/R MM
A medical oncologist discusses the significance of recent data and CAR T-cell therapy approvals in early relapsed/refractory multiple myeloma.
Case: A 70-Year-Old Man with Early Relapse Multiple Myeloma
Clinical Presentation:
- A 70-year-old man who was diagnosed 5 years ago with R-ISS stage 2/R2-ISS stage III lenalidomide refractory IgG-kappa multiple myeloma presents to his oncologist after two prior treatment regimens.
- Lives in a rural community
- PMH: hypertension controlled with lisinopril.
Prior Treatments:
- Patient received previous treatments with:
- D-VRd followed by ASCT with lenalidomide maintenance.
- Achieved VGPR, post-ASCT.
- Isa-Kd
- D-VRd followed by ASCT with lenalidomide maintenance.
Follow up and Clinical Workup at Relapse:
- Patient reports complaints of excessive fatigue and low back pain exacerbated by movement.
- Ca 10 mg/dL; SCr 2.9 mg/dL
- Hgb 6 g/dL; LDH 281 U/L; Albumin 3.4 g/dL
- Beta-2 microglobulin: 6 mg/dL
- BM Biopsy: 80% lambda light chain restricted.
- sIFE, IgG kappa present
- M protein 5 g/dL; sFLC kappa 240 mg/dL; sFLC lambda 2 mg/dL
- Kappa/Lambda ratio, 120
- FISH: amp 1q21+; t(14:16)
- Repeat Imaging:
- PET/CT scan showed multiple bone lesions in vertebrae without EMD.
- ECOG PS 0
- After discussion with his clinical team, the patient begins evaluations for CAR T referral.
- Patient ultimately proceeded to cilta-cel CAR T-cell infusion.
- Achieved stringent CR at day 30.
- Patient ultimately proceeded to cilta-cel CAR T-cell infusion.
Myeloma Research Sees Transformation Following ODAC Support For MRD End Point
May 20th 2025In an interview with Targeted Oncology, C. Ola Langren, MD, PhD, discussed the continuing impact of the groundbreaking FDA ODAC vote, the future of the Miami Myeloma MRD Meeting, and how researchers plan to continue expanding the role of MRD in myeloma and other hematologic malignancies.
Read More
Roundtable Roundup: Early CAR T-cell Therapy in Multiple Myeloma
May 19th 2025In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor (CAR) T-cell therapy.
Read More
